Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people.
AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Bio...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Conference item |
| Published: |
2014
|
| _version_ | 1797068850284462080 |
|---|---|
| author | Chen, Y Li, L Zhang, Q Clarke, R Chen, J Guo, Y Bian, Z Pan, X Peto, R Tao, R Shi, K Collins, R Ma, L Sun, H Chen, Z |
| author_facet | Chen, Y Li, L Zhang, Q Clarke, R Chen, J Guo, Y Bian, Z Pan, X Peto, R Tao, R Shi, K Collins, R Ma, L Sun, H Chen, Z |
| author_sort | Chen, Y |
| collection | OXFORD |
| description | AIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30-79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08-8.06) and diabetes (1.40; 1.28-1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension. |
| first_indexed | 2024-03-06T22:15:54Z |
| format | Conference item |
| id | oxford-uuid:53616f90-d0a1-408d-b3b7-4a53c40fc548 |
| institution | University of Oxford |
| last_indexed | 2024-03-06T22:15:54Z |
| publishDate | 2014 |
| record_format | dspace |
| spelling | oxford-uuid:53616f90-d0a1-408d-b3b7-4a53c40fc5482022-03-26T16:31:23ZUse of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people.Conference itemhttp://purl.org/coar/resource_type/c_5794uuid:53616f90-d0a1-408d-b3b7-4a53c40fc548Symplectic Elements at Oxford2014Chen, YLi, LZhang, QClarke, RChen, JGuo, YBian, ZPan, XPeto, RTao, RShi, KCollins, RMa, LSun, HChen, ZAIMS: Relatively little is known about the use of medication for the secondary prevention of cardiovascular disease (CVD) events in China, and the relevance to it of socioeconomic, lifestyle and health-related factors. METHODS AND RESULTS: We analysed cross-sectional data from the China Kadoorie Biobank (CKB) of 512,891 adults aged 30-79 years recruited from 1737 rural and urban communities in China. Information about doctor-diagnosed ischaemic heart disease (IHD) and stroke, and the use of medication for the secondary prevention of CVD events, were recorded by interview. Multivariate logistic regression was used to estimate odds ratios (ORs) for use of secondary preventive treatment, adjusting simultaneously for age, sex, area and education. Overall, 23,129 (4.5%) participants reported a history of CVD (3.0% IHD, 1.7% stroke). Among them, 35% reported current use of any of 6 classes of drug (anti-platelet, statins, diuretics, ACE-I, β-blockers or calcium-channel blockers) for the prevention of CVD events, with the rate of usage greater in those with older age, higher levels of income, education, BMI or blood pressure. The use of these agents was associated positively with history of diagnosed hypertension (OR 7.5; 95% confidence intervals: 7.08-8.06) and diabetes (1.40; 1.28-1.52) and inversely with self-rated health status, but there was no association with years since diagnosis. CONCLUSIONS: Despite recent improvements in hospital care in China, only one in three individuals with prior CVD was routinely treated with any proven secondary preventive drugs. The treatment rates were correlated with the existence of other risk factors, in particular evidence of hypertension. |
| spellingShingle | Chen, Y Li, L Zhang, Q Clarke, R Chen, J Guo, Y Bian, Z Pan, X Peto, R Tao, R Shi, K Collins, R Ma, L Sun, H Chen, Z Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title_full | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title_fullStr | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title_full_unstemmed | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title_short | Use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of China: China Kadoorie Biobank Study of 0.5 million people. |
| title_sort | use of drug treatment for secondary prevention of cardiovascular disease in urban and rural communities of china china kadoorie biobank study of 0 5 million people |
| work_keys_str_mv | AT cheny useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT lil useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT zhangq useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT clarker useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT chenj useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT guoy useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT bianz useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT panx useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT petor useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT taor useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT shik useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT collinsr useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT mal useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT sunh useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople AT chenz useofdrugtreatmentforsecondarypreventionofcardiovasculardiseaseinurbanandruralcommunitiesofchinachinakadooriebiobankstudyof05millionpeople |